Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Intismeran autogene |
| Trade Name | |
| Synonyms | mRNA4157|mRNA 4157|V940|V-940|V 940|mRNA-4157 |
| Drug Descriptions |
Intismeran autogene (mRNA-4157) is an mRNA-based lipid encapsulated personalized cancer vaccine encoding specific neoantigens, which potentially leads to enhanced anti-tumor immune response (Journal for ImmunoTherapy of Cancer 2020;8). |
| DrugClasses | |
| CAS Registry Number | 2931460-85-2 |
| NCIT ID | C146813 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| BCG solution + Intismeran autogene | BCG solution Intismeran autogene | 0 | 1 |
| Intismeran autogene | Intismeran autogene | 0 | 2 |
| Intismeran autogene + Pembrolizumab | Intismeran autogene Pembrolizumab | 0 | 9 |